责任编辑:乳腺癌互助君
参考资料:
[1] 夏雯,郑秋帆,覃涛,等..术前CA15-3和CEA水平在接受托瑞米芬治疗的管腔型可手术乳腺癌患者中的 预后价值[J]. 中山大学学报(医学科学版),2016,379(6);:858-868.
[2] Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor- positive advanced breast cancer[J]. J Clin Oncol, 2010, 28(30): 4594-4600.
[3] Robertson JF, Lindemann JP, Llombart- Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the firstline treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
[4] Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial[J]. J Natl Cancer Inst, 2014, 106(1): djt337.
[5] 江布英,吴耀忠,郭梓耘,等.他莫昔芬对绝经前后乳腺癌患者子宫内膜的影响[J].中国医药科学,2018,8(24):79-82.
[6] 黄汉生.乳腺癌内分泌治疗进展[J].中国现代医生,2020,58(14):178-181.
[7] REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials[J]. J Clin Oncol, 2016, 34(19): 2221-2231.
[8] SAHA P, REGAN M M, PAGANI O, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials [J]. J Clin Oncol, 2017, 35(27): 3113-3122.
[9] 徐涛,高磊.初探中医防治芳香化酶抑制剂引起骨相关症状的思路及方法[J].中医药学报,2016,44(3):97-98.
[10] 彭楠,王笑民.芳香化酶抑制剂治疗相关骨关节症状治疗现状[C]//中华中医药学会.2013 年全国中医肿瘤学术年会论文集,2013: 858-861.
[11] 王思源,王殊.抗缪勒管激素用于戈舍瑞林在年轻乳腺癌患者化疗期间保护卵巢储备功能的评价[J]. 北京大学学报(医学版),2019,51(3):536-541
[12] 兰波,马飞,徐兵河,等.戈舍瑞林联合阿那曲唑治疗绝经前乳腺癌患者的不良反应分析[J].中国肿瘤临床与康复,2015,22(9):1037-1040.
[13,14] 中国进展期乳腺癌共识指南2020(CABC3)[J].癌症进展,2020,18(19):1945-1964.
[15] 张瑾.乳腺癌内分泌治疗的进展 [J].中华乳腺病杂志:电子版,2011,5(1):7-11.
[16,17] 李新刚,赵志刚. 从临床疗效角度谈原研药和仿制药的区别[J]. 药品评价,2013,10(12):8-12+21.